GENMAB A/S GNMSF news, videos and press releases - Page 4
For more news please use our advanced search feature.
GENMAB A/S GNMSF - More news...
GENMAB A/S GNMSF - More news...
- Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosis
- Genmab Announces Financial Results for the First Nine Months of 2020
- Genmab Announces Data to be Presented at 2020 ASH Annual Meeting
- Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
- Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis
- Genmab to Host Capital Markets Day
- Genmab Announces Data to be Presented at SITC 35th Anniversary Annual Meeting
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
- Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
- Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis
- Genmab to Present at Morgan Stanley 18th Annual Global Healthcare Conference
- Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020
- Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
- U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Announces Financial Results for the First Half of 2020
- Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Major Shareholder Announcement
- Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
- Major Shareholder Announcement
- Major Shareholder Announcement
- Major Shareholder Announcement
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer